{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:15Z","timestamp":1787020695882,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["no. 269855"],"award-info":[{"award-number":["no. 269855"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["\u00c5pen prosjektst\u00f8tte"],"award-info":[{"award-number":["\u00c5pen prosjektst\u00f8tte"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatment uptake after the introduction of DAAs among patients receiving OAT in Sweden and Norway. We also aimed to evaluate predictors of DAAs treatment among OAT patients in both countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study was conducted with data from The Swedish Prescribed Drug Register and The Norwegian Prescription Database. We studied dispensed medications to calculate HCV treatment among OAT patients from 2014 to 2017 in Sweden and Norway. HCV prevalence was estimated from primary and secondary sources. Dispensations of medicines from different therapeutic areas, which served as proxy for co-morbidities in 2017, were conditionally adjusted for age, gender, and OAT medications. Logistic regression was used to evaluate these parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total 3529 individuals were identified with dispensed OAT in the Swedish cohort and 7739 individuals in the Norwegian cohort. HCV treatment was utilized by 407 persons in Sweden and 920 in Norway during the study period. Annual HCV and DAA treatment uptake increased in both countries. The estimated cumulative HCV treatment uptake at the end of 2017 was 31% in Norway and 28% in Sweden. DAA treatment was associated with increased age (aOR 1.8; 95% CI 1.0\u20133.2) and the dispensation of drugs used for diabetes (aOR 3.2; 95% CI 1.8\u20135.7) in Sweden. In Norway, lipid modifying agents and antibacterials were associated with decreased odds (aOR 0.4; 95%CI 0.2\u20130.9, aOR 0.8; 95%CI 0.6\u20131.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An increase in DAA treatment and HCV treatment uptake was observed among Swedish and Norwegian OAT patients whilst introducing new direct-acting antiviral treatment regimens. However, more than two thirds of the OAT population in Norway and Sweden were untreated at the beginning of 2018. A further scale-up is crucial in order to control and eliminate the HCV endemic among OAT patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13011-020-00286-2","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T03:02:49Z","timestamp":1593486169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-9354","authenticated-orcid":false,"given":"Christer F.","family":"Aas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn Henrik","family":"Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Odsbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Chalabianloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron G.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"issue":"4","key":"286_CR1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","volume":"9","author":"V Pecoraro","year":"2019","unstructured":"Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele V, Trenti T. New direct-acting antivirals for the treatment of patients with Hepatitis C virus infection: a systematic review of randomized controlled trials. J Clin Exp Hepatol. 2019;9(4):522\u201338.","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"286_CR2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","volume":"52","author":"BL Pearlman","year":"2011","unstructured":"Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52(7):889\u2013900.","journal-title":"Clin Infect Dis"},{"key":"286_CR3","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 2","key":"286_CR4","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","volume":"57","author":"EJ Aspinall","year":"2013","unstructured":"Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80\u20139.","journal-title":"Clin Infect Dis"},{"issue":"9791","key":"286_CR5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (London, England). 2011;378(9791):571\u201383.","journal-title":"Lancet (London, England)"},{"issue":"12","key":"286_CR6","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"key":"286_CR7","volume-title":"The Norwegian Centre for Addiction Research (SERAF)","author":"HBK Waal","year":"2018","unstructured":"Waal HBK, Clausen T, Lillevold PH, Skeie I. SERAF Report: Status 2017. MAR 20 years. Status, evaluations and perspectives. In: The Norwegian Centre for Addiction Research (SERAF); 2018."},{"issue":"1","key":"286_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12879-017-2631-2","volume":"17","author":"H Meijerink","year":"2017","unstructured":"Meijerink H, White RA, Lovlie A, de Blasio BF, Dalgard O, Amundsen EJ, Melum E, Klovstad H. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030. BMC Infect Dis. 2017;17(1):541.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"286_CR9","first-page":"569","volume":"50","author":"M Lagging","year":"2018","unstructured":"Lagging M, Wejstal R, Duberg AS, Aleman S, Weiland O, Westin J. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infect Dis (London, England). 2018;50(8):569\u201383.","journal-title":"Infect Dis (London, England)"},{"key":"286_CR10","volume-title":"The Norwegian Doctor Association (DNLF)","author":"The Norwegian Association of Infectious Diseases","year":"2019","unstructured":"The Norwegian Association of Infectious Diseases. Professional guidelines for diagnosing and treatment of Hepatitis C among adults. In: The Norwegian Doctor Association (DNLF); 2019."},{"key":"286_CR11","unstructured":"Hepatitis C - guidelines for health professionals. https:\/\/www.fhi.no\/nettpub\/smittevernveilederen\/sykdommer-a-a\/hepatitt-c%2D%2D-veileder-for-helsepers\/#forekomst-i-norge. Accessed 3 Apr 2019."},{"issue":"12","key":"286_CR12","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","volume":"5","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, Grebely J, Dumchev KV, Griffiths P, Hines L, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208\u201320.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"286_CR13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190146","volume":"13","author":"K Safreed-Harmon","year":"2018","unstructured":"Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV. Policy responses to hepatitis C in the Nordic countries: gaps and discrepant reporting in the Hep-Nordic study. PLoS One. 2018;13(1):e0190146.","journal-title":"PLoS One"},{"key":"286_CR14","first-page":"Cd012021","volume":"9","author":"L Platt","year":"2017","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:Cd012021.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"286_CR15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","volume":"3","author":"B Hajarizadeh","year":"2018","unstructured":"Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754\u201367.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"286_CR16","doi-asserted-by":"crossref","unstructured":"Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011. NO: 8 SN: 1465\u20131858.","DOI":"10.1002\/14651858.CD004145.pub4"},{"issue":"6","key":"286_CR17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","volume":"54","author":"NK Martin","year":"2011","unstructured":"Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137\u201344.","journal-title":"J Hepatol"},{"issue":"5","key":"286_CR18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","volume":"58","author":"NK Martin","year":"2013","unstructured":"Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (Baltimore, Md). 2013;58(5):1598\u2013609.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"286_CR19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","volume":"26","author":"J Grebely","year":"2015","unstructured":"Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(10):1028\u201338.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"286_CR20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166451","volume":"11","author":"H Midgard","year":"2016","unstructured":"Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O. Hepatitis C treatment uptake among patients who have received opioid substitution treatment: a population-based study. PLoS One. 2016;11(11):e0166451.","journal-title":"PLoS One"},{"issue":"2","key":"286_CR21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/02813432.2017.1333323","volume":"35","author":"TB Eide","year":"2017","unstructured":"Eide TB, Straand J, Bj\u00f6rkelund C, Kosunen E, Thorgeirsson O, Vedsted P, Rosvold EO. Differences in medical services in Nordic general practice: a comparative survey from the QUALICOPC study. Scand J Prim Health Care. 2017;35(2):153\u201361.","journal-title":"Scand J Prim Health Care"},{"key":"286_CR22","unstructured":"About the Norwegian Prescription Database. http:\/\/www.norpd.no\/Viktig.aspx. Accessed 13 Mar 2019."},{"issue":"1","key":"286_CR23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1186\/s12879-019-4598-7","volume":"19","author":"LT Fadnes","year":"2019","unstructured":"Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgard O, Vickerman P, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infect Dis. 2019;19(1):943.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"286_CR24","first-page":"728","volume":"49","author":"M Kaberg","year":"2017","unstructured":"Kaberg M, Hammarberg A, Lidman C, Weiland O. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program. Infect Dis (London, England). 2017;49(10):728\u201336.","journal-title":"Infect Dis (London, England)"},{"key":"286_CR25","unstructured":"ATC Classification Index with DDDs 2018. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 18 Nov 2018."},{"issue":"12","key":"286_CR26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","volume":"12","author":"JP Vandenbroucke","year":"2014","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg (London, England). 2014;12(12):1500\u201324.","journal-title":"Int J Surg (London, England)"},{"issue":"1","key":"286_CR27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","volume":"13","author":"JM Micallef","year":"2006","unstructured":"Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34\u201341.","journal-title":"J Viral Hepat"},{"issue":"8","key":"286_CR28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.12370","volume":"34","author":"M Alavi","year":"2014","unstructured":"Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, Tyndall MW, Grebely J. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2014;34(8):1198\u2013206.","journal-title":"Liver Int"},{"issue":"2","key":"286_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.idc.2018.02.001","volume":"32","author":"BL Norton","year":"2018","unstructured":"Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of chronic Hepatitis C in patients receiving opioid agonist therapy: a review of best practice. Infect Dis Clin N Am. 2018;32(2):347\u201370.","journal-title":"Infect Dis Clin N Am"},{"issue":"Suppl 1","key":"286_CR30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jvh.12875","volume":"25","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, et al. Hepatitis C: the beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018;25(Suppl 1):6\u201317.","journal-title":"J Viral Hepat"},{"key":"286_CR31","volume-title":"European HCV treatment access survey shows big variations in eligibility","author":"K Alcorn","year":"2017","unstructured":"Alcorn K: European HCV treatment access survey shows big variations in eligibility. AIDSmap. 2017."},{"key":"286_CR32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","volume":"47","author":"BL Norton","year":"2017","unstructured":"Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, Cunningham CO, Johnson N, Laraque F, Litwin AH. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196\u2013201.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"286_CR33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","volume":"165","author":"GJ Dore","year":"2016","unstructured":"Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, et al. Elbasvir-Grazoprevir to treat Hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625\u201334.","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"286_CR34","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/cid\/cit307","volume":"57","author":"J Reimer","year":"2013","unstructured":"Reimer J, Schmidt CS, Schulte B, Gansefort D, Golz J, Gerken G, Scherbaum N, Verthein U, Backmund M. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial. Clin Infect Dis. 2013;57(Suppl 2):S97\u2013104.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"286_CR35","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/cid\/cit301","volume":"57","author":"BP Grady","year":"2013","unstructured":"Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis. 2013;57(Suppl 2):S105\u201310.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"286_CR36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12879-019-4284-9","volume":"19","author":"R Han","year":"2019","unstructured":"Han R, Zhou J, Francois C, Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU\/EEA: a systematic review update. BMC Infect Dis. 2019;19(1):655.","journal-title":"BMC Infect Dis"},{"key":"286_CR37","volume-title":"Systematic review on hepatitis B and C prevalence in the EU\/EEA","author":"European Centre for Disease Prevention and Control","year":"2016","unstructured":"European Centre for Disease Prevention and Control: Systematic review on hepatitis B and C prevalence in the EU\/EEA. 2016."},{"key":"286_CR38","volume-title":"F\u00e6rre nye rusmisbrukere inn i LAR","author":"L Nilsen","year":"2017","unstructured":"Nilsen L. F\u00e6rre nye rusmisbrukere inn i LAR. Oslo: Dagens Medisin; 2017."},{"key":"286_CR39","volume-title":"ATLAS of substance use disorders: resources for the prevention and treatment of substance use disorders (SUD)","author":"World Health Organization","year":"2010","unstructured":"World Health Organization: ATLAS of substance use disorders: resources for the prevention and treatment of substance use disorders (SUD). Country Profile: SWEDEN 2010."},{"key":"286_CR40","volume-title":"Sweden, Country Drug Report 2019","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2019","unstructured":"European Monitoring Centre for Drugs and Drug Addiction: Sweden, Country Drug Report 2019. 2019."},{"issue":"9","key":"286_CR41","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/add.14217","volume":"113","author":"Z Ward","year":"2018","unstructured":"Ward Z, Platt L, Sweeney S, Hope VD, Maher L, Hutchinson S, Palmateer N, Smith J, Craine N, Taylor A, et al. Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people WHO inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? Addiction (Abingdon, England). 2018;113(9):1727\u201338.","journal-title":"Addiction (Abingdon, England)"},{"key":"286_CR42","volume-title":"Ministry of Health and Care Services","author":"Ministry of Health and Care Services","year":"2018","unstructured":"Ministry of Health and Care Services. National strategy against hepatitis 2018\u20132023. In: Ministry of Health and Care Services; 2018."},{"key":"286_CR43","volume-title":"H\u00e4lsofr\u00e4mjande och f\u00f6rebyggande arbete med hepatiter i Sverige - Kunskapsunderlag, analys och bed\u00f6mningar","author":"Folkeh\u00e4lsomyndigheten","year":"2019","unstructured":"Folkeh\u00e4lsomyndigheten: H\u00e4lsofr\u00e4mjande och f\u00f6rebyggande arbete med hepatiter i Sverige - Kunskapsunderlag, analys och bed\u00f6mningar. 2019."},{"key":"286_CR44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fendo.2015.00134","volume":"6","author":"SS Hammerstad","year":"2015","unstructured":"Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: a two-way association. Front Endocrinol. 2015;6:134.","journal-title":"Front Endocrinol"},{"issue":"10","key":"286_CR45","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S2468-1253(19)30227-4","volume":"4","author":"KK Lee","year":"2019","unstructured":"Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, et al. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol. 2019;4(10):794\u2013804.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"286_CR46","volume-title":"Komorbiditet \u2014 samf\u00f6rekomst av narkotikamissbruk och psykisk st\u00f6rning. Ett underskattat tillst\u00e5nd","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2004","unstructured":"European Monitoring Centre for Drugs and Drug Addiction: Komorbiditet \u2014 samf\u00f6rekomst av narkotikamissbruk och psykisk st\u00f6rning. Ett underskattat tillst\u00e5nd. 2004."}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-00286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-020-00286-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-00286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T19:37:06Z","timestamp":1624995426000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-020-00286-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1186\/s13011-020-00286-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-18790\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-18790\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21198\/v1","asserted-by":"object"}]},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"26 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Ethical Committee (no. 2018\/939), Norway, on June 19, 2018 and by the Regional Ethical Review Committee in Stockholm (no 2018\/2080\u201331\/1), Sweden, on November 14, 2018. No informed consent from the participants was required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I.O. is employed at the Centre for Pharmacoepidemiology, Karolinska Institutet, which receives grants from several entities (pharmaceutical companies, regulatory authorities, and contract research organizations) for performance of drug safety and drug utilization studies, unrelated to this work. None of the other authors have competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}